Article Text

Download PDFPDF
Mucinous ovarian cancer
  1. M. L. Harrison*,
  2. C. Jameson and
  3. M. E. Gore*
  1. * Departments of Medicine and
  2. Histopathology, Royal Marsden Hospital, London, United Kingdom
  1. Address correspondence and reprint requests to: Martin E. Gore, PhD, FRCP, Department of Medicine, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK. Email: martin.gore{at}


Mucinous epithelial ovarian cancer (mEOC) accounts for approximately 10% of EOCs. Patients presenting with early-stage disease have an excellent prognosis, however, those with advanced disease have a poor outcome with relative resistance to standard ovarian cancer chemotherapy. Molecular and genetic studies demonstrate differences between mucinous and serous EOC supporting the concept that these tumors develop along separate pathways. Together with the observed differences in clinical behavior and outcome for mEOC, there is a need to develop specific therapeutic strategies for this histologic subtype. The relative rarity of advanced mEOC has resulted in few patients enrolled in major ovarian cancer trials. The results of such trials may not necessarily reflect those specific to mEOC. Separate trials testing alternative chemotherapeutics are required. Metastatic mucinous tumors from other sites such as the gastrointestinal tract may present with ovarian involvement. For all mucinous tumors of the ovary, establishing primary as opposed to metastatic cancers is important. Clinical presentation, tumor markers, histologic, and immunohistochemical features are helpful in distinguishing most cases.

  • chemotherapy
  • epithelial ovarian cancer
  • molecular studies
  • mucinous
  • pathology

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.